
Experts weigh in on standout breast cancer, lung cancer, melanoma, and kidney cancer data presented at the 2026 ESMO Congress.
Hans J. Hammers, MD, PhD, associate professor, Internal Medicine, UT Southwestern Medical Center, discusses the next steps with immunotherapy for patients with renal cell carcinoma (RCC).
Hans J. Hammers, MD, PhD, associate professor, Internal Medicine, UT Southwestern Medical Center, discusses the next steps with immunotherapy for patients with renal cell carcinoma (RCC).
Data are still needed to determine the response of nivolumab (Opdivo) in certain subsets of patients, states Hammers. If there is a signal of clinical activity, it might be studied in combination with other regimens for this patient population.



